Exelixis, Inc. (EXEL) Presents at Morgan Stanley 23rd Annual Global

Company Overview - Exelixis is a commercial stage biotech company focused on oncology, with strong revenue growth attributed to its lead product, CABOMETYX [5]. - CABOMETYX, known generically as cabozantinib, is a leading VEGFR targeting TKI that addresses both primary tumor growth and resistance [5]. Product Information - CABOMETYX has been on the market for over 10 years and has received approvals for 7 to 8 different indications [5].